June 09, 2022
Federal Trade Commission staffers pressed their bid to block Illumina's $8 billion reacquisition of cancer testing outfit Grail during closing arguments, as the agency's administrative law judge questioned whether getting the case wrong could cost lives.
February 11, 2022
A D.C. federal judge on Friday granted the Federal Trade Commission's request to put on ice a lawsuit the agency filed demanding that Caris Life Sciences comply with subpoenas in the FTC's challenge to the planned merger of biotech firms Illumina and Grail.
December 02, 2021
Caris Life Sciences is fighting a subpoena in connection with the Federal Trade Commission's challenge of the Illumina-Grail deal, arguing the broad scope of the requests puts its trade secrets at risk.